151 related articles for article (PubMed ID: 32699144)
1. A connectomics approach to understanding a retinal disease.
Zucker CL; Bernstein PS; Schalek RL; Lichtman JW; Dowling JE
Proc Natl Acad Sci U S A; 2020 Aug; 117(31):18780-18787. PubMed ID: 32699144
[TBL] [Abstract][Full Text] [Related]
2. Anti-retinal IgG antibodies in patients with early and advanced type 2 macular telangiectasia.
McLenachan S; Balaratnasingam C; Heath Jeffery RC; Chen SC; Zhang D; Chan G; Dolz-Marco R; Bacci T; Lo J; Wiffen S; Yannuzzi LA; Chen FK
Exp Eye Res; 2022 May; 218():109024. PubMed ID: 35271830
[TBL] [Abstract][Full Text] [Related]
3. Systemic lipid dysregulation is a risk factor for macular neurodegenerative disease.
Bonelli R; Woods SM; Ansell BRE; Heeren TFC; Egan CA; Khan KN; Guymer R; Trombley J; Friedlander M; Bahlo M; Fruttiger M
Sci Rep; 2020 Jul; 10(1):12165. PubMed ID: 32699277
[TBL] [Abstract][Full Text] [Related]
4. Contextual influences in the peripheral retina of patients with macular degeneration.
Contemori G; Battaglini L; Casco C
Sci Rep; 2019 Jun; 9(1):9284. PubMed ID: 31243292
[TBL] [Abstract][Full Text] [Related]
5. Anti-retinal antibodies in patients with macular telangiectasia type 2.
Zhu L; Shen W; Zhu M; Coorey NJ; Nguyen AP; Barthelmes D; Gillies MC
Invest Ophthalmol Vis Sci; 2013 Aug; 54(8):5675-83. PubMed ID: 23882694
[TBL] [Abstract][Full Text] [Related]
6. Improvements in visual acuity and macular morphology following cessation of anti-estrogen drugs in a patient with anti-estrogen maculopathy resembling macular telangiectasia type 2: a pathogenic hypothesis.
Shinkai A; Saito W; Hashimoto Y; Ishida S
BMC Ophthalmol; 2019 Dec; 19(1):267. PubMed ID: 31888549
[TBL] [Abstract][Full Text] [Related]
7. Retinal vascular density evaluated by optical coherence tomography angiography in macular telangiectasia type 2.
Dogan B; Erol MK; Akidan M; Suren E; Akar Y
Int Ophthalmol; 2019 Oct; 39(10):2245-2256. PubMed ID: 30607862
[TBL] [Abstract][Full Text] [Related]
8. Outer retinal hyperreflective spots on spectral-domain optical coherence tomography in macular telangiectasia type 2.
Baumüller S; Charbel Issa P; Scholl HP; Schmitz-Valckenberg S; Holz FG
Ophthalmology; 2010 Nov; 117(11):2162-8. PubMed ID: 20557944
[TBL] [Abstract][Full Text] [Related]
9. Retinal ganglion cells thinning in eyes with nonproliferative idiopathic macular telangiectasia type 2A.
Chhablani J; Rao HB; Begum VU; Jonnadulla GB; Goud A; Barteselli G
Invest Ophthalmol Vis Sci; 2015 Feb; 56(2):1416-22. PubMed ID: 25655800
[TBL] [Abstract][Full Text] [Related]
10. iPSC-derived retinal pigmented epithelial cells from patients with macular telangiectasia show decreased mitochondrial function.
Eade KT; Ansell BRE; Giles S; Fallon R; Harkins-Perry S; Nagasaki T; Tzaridis S; Wallace M; Mills EA; Farashi S; Johnson A; Sauer L; Hart B; Diaz-Rubio ME; Bahlo M; Metallo C; Allikmets R; Gantner ML; Bernstein PS; Friedlander M
J Clin Invest; 2023 May; 133(9):. PubMed ID: 37115691
[TBL] [Abstract][Full Text] [Related]
11. Idiopathic preretinal glia in aging and age-related macular degeneration.
Edwards MM; McLeod DS; Bhutto IA; Villalonga MB; Seddon JM; Lutty GA
Exp Eye Res; 2016 Sep; 150():44-61. PubMed ID: 26220834
[TBL] [Abstract][Full Text] [Related]
12. Overlap between telangiectasia and photoreceptor loss increases with progression of macular telangiectasia type 2.
Micevych PS; Lee HE; Fawzi AA
PLoS One; 2019; 14(10):e0224393. PubMed ID: 31658282
[TBL] [Abstract][Full Text] [Related]
13. Potential Effects of Hormone Therapy in Type 2 Idiopathic Macular Telangiectasia.
Wolf-Schnurrbusch UEK; Leung I; Sallo FB; Clemons TE; Chew EY; Bird AC; Peto T;
Ophthalmic Res; 2018; 60(1):38-42. PubMed ID: 28903123
[TBL] [Abstract][Full Text] [Related]
14. [The role of Müller cells in the formation and development of macular hole].
Liu CY; Zhang XM; Yue HF; Shi YX
Zhonghua Yan Ke Za Zhi; 2023 Nov; 59(11):948-953. PubMed ID: 37641407
[TBL] [Abstract][Full Text] [Related]
15. Quantification of reduced macular pigment optical density in the central retina in macular telangiectasia type 2.
Charbel Issa P; van der Veen RL; Stijfs A; Holz FG; Scholl HP; Berendschot TT
Exp Eye Res; 2009 Jun; 89(1):25-31. PubMed ID: 19233170
[TBL] [Abstract][Full Text] [Related]
16. Effect of glucocorticoids on neuronal and vascular pathology in a transgenic model of selective Müller cell ablation.
Shen W; Lee SR; Araujo J; Chung SH; Zhu L; Gillies MC
Glia; 2014 Jul; 62(7):1110-24. PubMed ID: 24687761
[TBL] [Abstract][Full Text] [Related]
17. Progression of vascular changes in macular telangiectasia type 2: comparison between SD-OCT and OCT angiography.
Pauleikhoff D; Gunnemann F; Book M; Rothaus K
Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1381-1392. PubMed ID: 31093765
[TBL] [Abstract][Full Text] [Related]
18. Ultrastructure and clinicopathologic correlation of idiopathic preretinal macular fibrosis.
Bellhorn MB; Friedman AH; Wise GN; Henkind P
Am J Ophthalmol; 1975 Mar; 79(3):366-73. PubMed ID: 1121993
[TBL] [Abstract][Full Text] [Related]
19. Demographic features of idiopathic macular telangiectasia in Korean patients.
Kim SH; Oh J; Ahn SE; Park CY; Oh JH
Korean J Ophthalmol; 2015 Jun; 29(3):155-9. PubMed ID: 26028942
[TBL] [Abstract][Full Text] [Related]
20. FUNDUS-WIDE SUBRETINAL AND PIGMENT EPITHELIAL ABNORMALITIES IN MACULAR TELANGIECTASIA TYPE 2.
Powner MB; Woods SM; Zhu M; Gillies MC; Bernstein PS; Hageman GS; Comer GM; Egan C; Fruttiger M
Retina; 2018 Jan; 38 Suppl 1():S105-S113. PubMed ID: 29045321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
